Table 2 Comparison of mesenchymal stem cell cellular therapy with angiogenesis gene therapy in critical limb ischemia
From: Therapeutic potential for mesenchymal stem cell transplantation in critical limb ischemia
| Â | MSC cellular therapy | Â | |
|---|---|---|---|
| Â | Autologous MSCs | Allogeneic MSCs | Angiogenesis gene therapy |
Angiogenesis factors | Secretion of multiple factors | Secretion of multiple factors | Specific to the gene |
Mode of action | Multiple roles: angiogenesis immunomodulation differentiation | Multiple roles: angiogenesis immunomodulation differentiation | Specific to the gene |
Immunogenicity | None | Yes | Yes |
Intrinsic limitation | Cell-related dysfunction | No cell-related dysfunction | Gene transfer-related issue |
Feasibility as an 'off the shelf' | No | Yes | Yes |
Transmission of zoonoses | No | Unknown | Unknown |
Predictable pharmacokinetics and pharmacodynamics | No | No | Yes |
Cost of production | Expensive | Expensive | Expensive |
Requirement for karyotyping | Yes | Yes | No |
Mass production | No | Yes | Yes |